Cantor Fitzgerald Reiterates Buy Rating on Atrium Therapeutics

Cantor Fitzgerald reiterated its buy rating for Atrium Therapeutics, Inc. (NasdaqGS:RNA) on June 18, 2026. The firm set a price target of $25, signaling confidence in the biopharmaceutical company's future prospects.

Atrium Therapeutics, Inc. Stock Up 1.4%

Shares of NasdaqGS:RNA traded near $12.48. Atrium Therapeutics has a market cap of approximately $213.5 million. The company focuses on RNA-based therapies for cardiomyopathies, with its stock reaching a 52-week high of $16.77 and a low of $11.4. The stock's 50-day moving average is $13.02, while the 200-day moving average is $13.36. The company is not currently profitable, reflected in its negative forward P/E ratio.

Recent Earnings

For its latest quarter, Atrium Therapeutics reported revenue of $36.68 million, showing a growth of 11.5%. Despite this, the company recorded a net margin of -160%, indicating it is still in the development phase with substantial costs. The next earnings report is expected on May 11, 2026.

Insider Buying and Selling at Atrium Therapeutics, Inc.

On April 20, 2026, several insiders purchased shares of Atrium Therapeutics. CEO Kathleen Gallagher bought 102,500 shares, while Chief Strategy Officer Rocio Martin acquired 60,000 shares. Chief Medical Officer Steven Hughes, Chief Corporate Affairs Officer Stephanie Kenney, and CFO Brendan Winslow each purchased shares, showing insider confidence in the company's direction.

Analysts Set New Price Targets

On June 18, 2026, Cantor Fitzgerald reiterated its buy rating and set a $25 price target for Atrium Therapeutics. This aligns with other analysts like Leerink Partners and Wells Fargo, who also initiated buy ratings with the same target price earlier this year. The consensus target mean price stands at $25, with two analysts currently covering the stock.

About Atrium Therapeutics

Atrium Therapeutics, Inc., headquartered in San Diego, California, is a biotechnology company specializing in RNA therapeutics aimed at treating cardiomyopathies. Led by CEO Kathleen P. Gallagher, the firm is developing therapies like ATR 1072 and ATR 1086, which target genetic conditions affecting the heart. Established in 2025, the company is part of the healthcare sector, with a focus on innovative treatments for cardiac diseases.

Bottom Line

Cantor Fitzgerald's reiterated buy rating and $25 price target reflect a positive outlook on Atrium Therapeutics' potential in RNA therapeutics. Investors watch these analyst ratings closely, as they provide insights into market expectations. However, it's important to remember that these ratings are based on past performance and projections, which might not reflect current market conditions.